Advanced Search

Technical Analysis for SOLY - Soliton, Inc.

Grade Last Price % Change Price Change
grade D 12.13 0.00% 0.00
SOLY closed up 2.97 percent on Thursday, January 16, 2020, on 68 percent of normal volume.
3 Watchers
Watchlist Portfolio

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical SOLY trend table...
Date Alert Name Type % Chg
Pocket Pivot Bullish Swing Setup 0.00%
Spinning Top Other 2.97%
NR7 Range Contraction 2.97%
Inside Day Range Contraction 2.97%
Bearish Engulfing Bearish 3.59%
Up 3 Days in a Row Strength 1.85%
Up 4 Days in a Row Strength 1.85%
Up 5 Days in a Row Strength 1.85%
Up 3 Days in a Row Strength 2.88%
Up 4 Days in a Row Strength 2.88%
Older EOD signals for SOLY ...
View Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
SOLY Chart by TradingView
Basic chart:

Profile

Soliton, Inc. is a pre-revenue stage medical device company with a novel and proprietary platform technology licensed from MD Anderson. The Company’s first commercial product uses rapid pulses of designed acoustic shockwaves to dramatically accelerate the removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in bringing this device to the market. The Company expects to file for premarket clearance with the U.S. Food and Drug Administration ("FDA") for its first device in the first quarter of 2019 and expects to receive clearance to market the device in mid-2019.
Health Medical Device Platform Technology

Is SOLY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

Recent News

Date Title
Jan 13 Soliton To Announce Keloid and Hypertrophic Scar Clinical 12-Week Trial Data at Maui Derm Meeting
Jan 7 Soliton Appoints Robert "Joe" Mills as Vice President of Supply Chain
Dec 18 Soliton Announces Successful Completion of Safety Testing at SGS to Support FDA Filing for Second Generation Device
Dec 10 Soliton Appoints Mary Stoll as Senior Director of Clinical Development
Dec 3 Soliton Initiates Significant Step Towards Commercialization
Nov 22 5 Lottery Stocks With Huge Upside — And a Real Chance of $0
Nov 21 Soliton and Emphysys Enter Into a 3-year Development Agreement
Nov 12 Soliton Announces First Follow-up Visit Conducted in the Pivotal Cellulite Clinical Trial
Nov 8 Soliton holders file to offer 1M shares
Nov 5 Soliton Completes Treatment of All Patients in Pivotal Cellulite Trial
See more SOLY news...

Indicators

Indicator Value
52 Week High 29.0
52 Week Low 4.12
Average Volume 163,287
200-Day Moving Average 12.41
50-Day Moving Average 11.05
20-Day Moving Average 11.42
10-Day Moving Average 11.61
Average True Range 0.59
ADX 20.2
+DI 28.18
-DI 15.19
Chandelier Exit (Long, 3 ATRs ) 11.12
Chandelier Exit (Short, 3 ATRs ) 12.02
Upper Bollinger Band 12.40
Lower Bollinger Band 10.44
Percent B (%b) 0.86
BandWidth 17.15
MACD Line 0.21
MACD Signal Line 0.13
MACD Histogram 0.0793
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.99
Resistance 3 (R3) 12.92 12.57 12.84
Resistance 2 (R2) 12.57 12.35 12.60 12.79
Resistance 1 (R1) 12.35 12.22 12.46 12.42 12.75
Pivot Point 12.00 12.00 12.06 12.03 12.00
Support 1 (S1) 11.78 11.78 11.89 11.85 11.51
Support 2 (S2) 11.43 11.65 11.46 11.47
Support 3 (S3) 11.21 11.43 11.42
Support 4 (S4) 11.28